Correspondence 0001213900-25-043071 from MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: May 14, 2025 · CIK: 0001874252 · Accession: 0001213900-25-043071
AI Filing Summary & Sentiment
File numbers found in text: 333-287249
Show Raw Text
CORRESP 1 filename1.htm MAXIM GROUP LLC 300 Park Avenue New York, New York 10022 May 14, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, NE Washington, D.C. 20549 Re: Mainz Biomed N.V. Registration Statement on Form F-1 (Registration No. 333-287249) Dear Ms. Sheppard: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), the undersigned, as placement agent in connection with the above referenced Registration Statement relating to the offer and issuance by the Registrant of certain of its securities, hereby joins the Registrant's request that the effective date of the Registration Statement be accelerated so that it shall be declared effective at 5:00 PM Eastern Time on Thursday, May 15, 2025, or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, we wish to advise you that the placement agent has distributed as many copies of the Preliminary Prospectus, dated May 14, 2025, to investors, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus. This is to further advise you that the placement agent has and will continue to comply with Rule 15c2-8 of the Securities Exchange Act of 1934, as amended, with regard to the Preliminary Prospectus and any amended Prospectus. If you require any additional information with respect to this letter, please contact Ali Panjwani of Pryor Cashman LLP at (212) 326-0820. Very truly yours, MAXIM GROUP LLC By: /s/ Ritesh M. Veera Name: Ritesh M. Veera Title: Co-Head of Investment Banking